OPT
Closed
Opthea Ltd
3.41
0.00 (0.00%)
Last Update: 15 Apr 2025 16:30:00
Yesterday: 3.41
Day's Range: 3.41 - 3.41
Send
sign up or login to leave a comment!
When Written:
3.55
Opthea Ltd is a biotechnology company that is focused on developing novel therapies for the treatment of eye diseases. The company is based in Melbourne, Australia and was founded in 2005. Opthea's lead drug candidate is OPT-302, which is a soluble form of VEGFR-3 that is designed to block the activity of VEGF-C and VEGF-D. These proteins are known to play a role in the development of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT-302 is currently in Phase 3 clinical trials for the treatment of wet AMD and DME. In addition to OPT-302, Opthea is also developing a pipeline of other drug candidates for the treatment of various eye diseases.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








